8-K: Passage Bio Reports 2025 Results, Advances Gene Therapy Pipeline

Passage Bio announced its full-year 2025 financial results and provided key updates on its clinical programs for frontotemporal dementia and preclinical work for Huntington's disease.

Summary

• Passage Bio reported a net loss of $45.5 million, or $14.35 per basic and diluted share, for the year ended December 31, 2025, a reduction from $64.8 million, or $21.04 per share, in 2024.
• Cash and cash equivalents were $46.3 million as of December 31, 2025, with a projected cash runway through the first quarter of 2027.
• Research and Development (R&D) expenses decreased to $23.3 million for 2025 from $40.2 million in 2024.
• General and Administrative (G&A) expenses decreased to $19.9 million for 2025 from $25.0 million in 2024.
• The company enrolled the first three FTD-GRN patients in Cohort 3 of the upliFT-D study and treated the first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4.
• Passage Bio is advancing a preclinical program for Huntington's disease, with a clinical candidate selection expected in the second half of 2026.
• Updated interim safety and biomarker data from the upliFT-D study and regulatory feedback on FTD-GRN registrational trial design are anticipated in the first half of 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to significant progress in clinical trials, promising interim data for PBFT02, and improved financial management leading to a reduced net loss and extended cash runway, balanced by the inherent risks of a clinical-stage biotech.

Positives

• Net loss significantly decreased to $45.5 million in 2025 from $64.8 million in 2024, indicating improved financial efficiency.
• R&D expenses decreased by approximately 42% and G&A expenses decreased by approximately 20% year-over-year, reflecting cost management.
• The company has extended its cash runway through the first quarter of 2027, providing longer operational stability.
• Significant clinical progress was made with the enrollment of the first three FTD-GRN patients in Cohort 3 and the treatment of the first FTD-C9orf72 patient in Cohort 4 of the upliFT-D study.
• PBFT02 demonstrated robust and durable increases in CSF Progranulin (PGRN) in FTD-GRN patients, with a mean of >6 ng/mL at 12 months for Dose 1 patients and Patient 8 (Dose 2) increasing from 1.5 ng/mL to 7.6 ng/mL at M1.
• Plasma NfL showed early evidence of improvement in a disease progression biomarker compared to natural history data, suggesting potential therapeutic effect.
• The PBFT02 interim safety profile was generally well tolerated, with no serious adverse events related to Dose 2 and no evidence of thrombotic microangiopathy or dorsal root ganglion toxicity.
• A high-productivity, suspension-based manufacturing process has been completed, estimated to yield over 1,000 doses per single production lot, supporting late-stage development.

Negatives

• Total cash, cash equivalents, and marketable securities decreased from $76.8 million as of December 31, 2024, to $46.3 million as of December 31, 2025, indicating ongoing cash burn.
• The company continues to operate at a significant net loss, totaling $45.5 million for the year ended December 31, 2025.

Risks

• Ability to develop and obtain regulatory approval for product candidates.
• Timing and results of preclinical studies and clinical trials.
• Risks associated with clinical trials, including managing clinical activities, unexpected concerns from additional data, regulatory authorities requiring more information or delaying approval.
• The occurrence of adverse safety events.
• The risk that positive results in a preclinical study or early-stage clinical trial may not be replicated in subsequent trials or predictive of results in later-stage clinical trials.
• Failure to protect and enforce intellectual property and other proprietary rights.
• Dependence on collaborators and other third parties for the development and manufacture of product candidates and other aspects of the business, which are outside of full control.
• Risks associated with current and potential delays, work stoppages, or supply chain disruptions.

Future Outlook

Passage Bio anticipates reporting updated interim safety and biomarker data from Dose 2 of the upliFT-D study and seeking regulatory feedback on the FTD-GRN registrational trial design in the first half of 2026. The company also expects to declare a clinical candidate for its Huntington's disease program in the second half of 2026. Current cash and cash equivalents are expected to fund operations through the first quarter of 2027.

Management Comments

• "We are proud of the progress made in 2025 as we meaningfully advanced our PBFT02 clinical program for the treatment of genetic forms of frontotemporal dementia."
• "As we enter 2026, we are excited by the strong enrollment momentum in our upliFT-D clinical study and look forward to sharing important data and regulatory updates in the first half of the year."
• "FTD is a devastating disease, and the clinical unmet need remains substantial. We remain committed to advancing our program in the hope that we might one day offer patients and their families a therapy to redefine the course of their disease."

Industry Context

StockSavvy.ai notes that Passage Bio operates in the highly competitive and innovative field of genetic medicines for neurodegenerative diseases, an area with significant unmet medical needs. The company's focus on gene therapy for conditions like FTD-GRN and Huntington's disease aligns with broader industry trends towards precision medicine and one-time curative approaches. The progress in clinical trials for PBFT02 and the advancement of its preclinical HD program position Passage Bio as a key player in developing novel treatments for these devastating conditions.

Comparison to Industry Standards

• PBFT02, an AAV1 gene therapy delivering GRN via intra-cisterna magna (ICM) administration, is positioned as a one-time, non-surgical treatment.
• This contrasts with an unnamed competitor's AAV9 gene therapy delivering GRN via intrathalamic (neurosurgical, lengthy) administration, also a one-time therapy.
• Another unnamed competitor offers PGRN replacement therapy via protein transport vehicle, administered intravenously (IV) with chronic dosing (approximately every 4 weeks).
• PBFT02's ability to achieve CSF PGRN levels of >6 ng/mL at 12 months (mean; n=4) and durable elevation at 18 months (n=2) is highlighted as potentially best-in-class, aiming for the highest progranulin levels among one-time therapies.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials continue to show positive results and lead to regulatory approvals, but also face dilution risk from future capital needs.
• Patients: Offers hope for new, disease-modifying therapies for severe neurodegenerative conditions like FTD and Huntington's disease, which currently have significant unmet needs.
• Employees: Continued employment and focus on advancing innovative genetic medicines.
• Regulatory Authorities: Will be engaged in providing feedback on trial designs and reviewing future data for potential approvals.

Next Steps

• Report updated interim safety and biomarker data from Dose 2 in FTD patients in 1H 2026.
• Seek regulatory feedback on registrational trial design in FTD-GRN in 1H 2026.
• Declare a clinical candidate for Huntington's disease in 2H 2026.

Key Dates

Recommendation

A seasoned investor would likely recommend a 'hold' for Passage Bio. While the company has demonstrated significant clinical progress with PBFT02, including promising interim safety and biomarker data, and has improved its financial position by reducing net loss and extending its cash runway, it remains a clinical-stage biotech. The inherent risks associated with drug development, regulatory hurdles, and the need for future capital to bring products to market warrant a cautious approach. The positive developments suggest potential, but the long path to commercialization and the competitive landscape mean it's not yet a 'strong buy' for most, nor a 'sell' given the progress.

Keywords

Gene therapy, Neurodegenerative diseases, Frontotemporal dementia, Huntington's disease, PBFT02, Clinical trial, Biomarkers, Genetic medicine, Rare disease, AAV1